These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38734524)

  • 1. Risk of Enzyme- and Transporter-mediated Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2022: A Detailed Analysis of In Vitro and Clinical Data Available in New Drug Application Reviews.
    Yu J; Wang Y; Ragueneau-Majlessi I
    Clin Ther; 2024 Jun; 46(6):499-508. PubMed ID: 38734524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
    Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
    Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations.
    Yu J; Wang Y; Ragueneau-Majlessi I
    Drug Metab Dispos; 2022 Jan; 50(1):1-7. PubMed ID: 34620694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications.
    Yu J; Wang Y; Ragueneau-Majlessi I
    Clin Ther; 2022 Nov; 44(11):1536-1544. PubMed ID: 36210218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016.
    Yu J; Zhou Z; Tay-Sontheimer J; Levy RH; Ragueneau-Majlessi I
    Drug Metab Dispos; 2018 Jun; 46(6):835-845. PubMed ID: 29572333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014.
    Yu J; Ritchie TK; Zhou Z; Ragueneau-Majlessi I
    Drug Metab Dispos; 2016 Jan; 44(1):83-101. PubMed ID: 26424199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.
    Yu J; Ritchie TK; Mulgaonkar A; Ragueneau-Majlessi I
    Drug Metab Dispos; 2014 Dec; 42(12):1991-2001. PubMed ID: 25271211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015.
    Yu J; Zhou Z; Owens KH; Ritchie TK; Ragueneau-Majlessi I
    Drug Metab Dispos; 2017 Jan; 45(1):86-108. PubMed ID: 27821435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
    Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
    Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
    Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
    Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model.
    Asano S; Kurosaki C; Mori Y; Shigemi R
    Drug Metab Pharmacokinet; 2024 Feb; 54():100531. PubMed ID: 38064927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
    Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
    J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
    Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
    Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information.
    Ohno Y; Hisaka A; Ueno M; Suzuki H
    Clin Pharmacokinet; 2008; 47(10):669-80. PubMed ID: 18783297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
    Varma MV; El-Kattan AF
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are circulating metabolites important in pharmacokinetic drug-drug interactions? A retroanalysis of clinical data.
    Zhao YS; Chen F; Li L
    Curr Drug Metab; 2014; 15(8):767-90. PubMed ID: 25705906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
    Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.
    Darwich AS; Neuhoff S; Jamei M; Rostami-Hodjegan A
    Curr Drug Metab; 2010 Nov; 11(9):716-29. PubMed ID: 21189140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
    Vourvahis M; Byon W; Chang C; Le V; Diehl A; Graham D; Tripathy S; Raha N; Luo L; Mathialagan S; Dowty M; Rodrigues AD; Malhotra B
    Clin Pharmacol Ther; 2022 Sep; 112(3):665-675. PubMed ID: 35344588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.